Decide which biopharma assets to go after

Sleuth maps every program, deal, and company, then scores each one on criteria built for your question. It shows what made the list, what didn’t, and why.

What teams do with Sleuth

“All the strategy that used to be proprietary to pharma — the ‘game within the game’ that actually drives indication decisions — Sleuth made that accessible to a nine-person biotech. I think it’s the most disruptive, amazing thing for small organizations like us. A massive, massive unlock.”

Danny Wells

Danny Wells

CEO, Epana Bio

“What makes Sleuth stand out is its rare combination of speed and credibility. The output is factual, well-structured, and decision-useful, making it a valuable input into internal discussions and executive conversations. It has raised our expectations for how quickly broad complexity can be translated into a clearer, more refined strategic narrative.”

Alex Cogdill

Alex Cogdill

Head of Strategic Initiatives, Global BD, Daiichi Sankyo

Epana Bio
Daiichi Sankyo
LionBio
Juvena Therapeutics
Pencil Biosciences
Sibylla Biotech
Westlake BioPartners
PJT Partners
vTv Therapeutics
Data

Start from the whole landscape

Sleuth pulls trials, drugs, companies, and deals from all the public sources you’d expect, plus analyst research, Chinese sources, and proprietary signals you can’t get elsewhere.

Public data

Registries, regulators, journals, and company filings across the US, Europe, and Asia, collected from the source and kept current.

Licensed research

Sell-side research from banks and brokers, included in every plan, searchable next to everything else, and ready to use in your own analysis.

China coverage

Chinese programs show up in the same search as everyone else’s. Sleuth collects them from China’s registries, regulators, exchanges, broker research, and WeChat accounts, and translates them.

Proprietary signals

Sleuth tracks which targets and indications are gaining attention across the bioeconomy, from signals only Sleuth has.

Who is running what study, where, and at what stage

  • ClinicalTrials.govGlobal
  • EU Clinical Trials Register (EudraCT)EU
  • ISRCTNUK
  • ChiCTRChina
  • jRCTJapan
  • ANZCTRAPAC
  • ReBECLatAm
  • CRISKorea
  • IRCTMiddle East and Africa
  • WHO ICTRPGlobal
  • EU CTISEU
  • China Drug Trial Registration Platform (CDE)China
  • CTRIAPAC
  • RPCECLatAm
  • PACTRMiddle East and Africa
  • and 6 more
Trial registries

Who is running what study, where, and at what stage

  • ClinicalTrials.govGlobal
  • EU Clinical Trials Register (EudraCT)EU
  • ISRCTNUK
  • ChiCTRChina
  • jRCTJapan
  • ANZCTRAPAC
  • ReBECLatAm
  • CRISKorea
  • IRCTMiddle East and Africa
  • and 12 more
Regulators and safety

What was approved, designated, delayed, or rejected, and what safety signals followed

  • FDA drug labels (openFDA / SPL)US
  • EMA CHMP opinions and meeting highlightsEU
  • MHRAUK
  • NMPAChina
  • PMDAJapan
  • Health Canada Drug Product DatabaseCanada
  • TGA Australian Register of Therapeutic Goods (ARTG)APAC
  • Project OrbisGlobal
  • FAERS (via openFDA)US
  • and 40 more
Literature and medical meetings

What the published science says, and what was presented before it reached a journal

  • PubMed / MEDLINEGlobal
  • Europe PMCEU
  • Chinese-language journals, theses, and conference papersChina
  • PubMed Central Open AccessGlobal
  • Select peer-reviewed clinical papersGlobal
  • bioRxivGlobal
  • 364 medical meetings in 20 therapy areasGlobal
  • NIH RePORTERUS
  • EU CORDISEU
  • and 5 more
Patients, treatment, and pricing

How many patients there are, how they’re treated, and what a drug costs

  • SEERUS
  • Eurostat health databaseEU
  • China CDCChina
  • WHO Global Health ObservatoryGlobal
  • HHS HIV guidelinesUS
  • CMS ASP pricing filesUS
  • NICE technology appraisalsUK
  • G-BA (AMNOG)EU
  • China National Reimbursement Drug List (NHSA)China
  • and 19 more
Company disclosures

What companies are required to disclose, and what they choose to say

  • SEC EDGARUS
  • HKEXnewsChina
  • EDINETJapan
  • DARTKorea
  • Company pipeline pagesGlobal
  • Company press releasesGlobal
  • Corporate and investor presentationsGlobal
  • Earnings call transcriptsGlobal
  • Investor day and R&D day materialsGlobal
  • and 11 more
Patents

Who owns what, and when exclusivity ends

  • US Patent and Trademark OfficeUS
  • European Patent OfficeEU
  • Japan Patent OfficeJapan
  • China National Intellectual Property AdministrationChina
  • WIPO PCT applicationsGlobal
  • Orange Book patents and exclusivitiesUS
  • Paragraph IV certifications listUS
  • Purple Book patent listsUS
News and social signals

What happened this week, and early signals outside formal disclosure

  • Business WireGlobal
  • PR NewswireGlobal
  • GlobeNewswireGlobal
  • Biotech and pharma trade pressGlobal
  • WeChat official accountsChina
  • Company job postingsGlobal
  • People and executive movesGlobal
  • Social posts from companies, KOLs, and analystsGlobal
  • Biotech podcasts and webinarsGlobal
Sell-side research

How the Street sizes, forecasts, and values drugs and companies.

  • Global investment banks
  • US healthcare and mid-market banks
  • European brokers
  • Independent and sponsored research
  • Consulting and industry research
  • Historical archives
Biology and disease reference

What each disease, target, gene, and compound is, defined once for every record

  • Disease OntologyGlobal
  • ICD-10-CMUS
  • MONDOGlobal
  • NCI ThesaurusUS
  • MeSHGlobal
  • FDA Global Substance Registration System (UNII)US
  • ICD-11Global
  • RxNormUS
  • Orphanet nomenclatureGlobal
  • and 9 more
See every source in the knowledge base

What teams use today

Good forWhere it falls short
ChatGPT and Claude
Good forQuick questions and first drafts
Where it falls shortBuilt from the open web each time. Some of it’s wrong, and it’s difficult to tell where.
Databases
Good forConsensus forecasts, sales history, and the standard numbers finance teams model on
Where it falls shortTens of thousands of dollars a seat each year, the same data for everyone, and the ranking still happens in Excel.
Consultants
Good forExpert interviews and outside validation
Where it falls shortSix to eight weeks, a six-figure fee, and a deck that doesn’t change once it’s delivered.
Sleuth
Datasets built for your question, a source behind every value, and a deck that stays current, from $249 a month.
See how Sleuth compares

Build analyses like this one for your own landscape

Explore our map of the cancer targets once called undruggable. Click any target to see the programs against it, which ones stalled, and the reasons on record.

The undruggable cancer targets crossing into the clinic: target map by family with p53 R175H open

Sleuth Intel Hub

New analyses, interactive landscapes, and quarterly reports, built with the same tools you can use with Sleuth.

Browse the Intel Hub

Frequently asked questions

How is Sleuth different from ChatGPT or Claude?

Sleuth gives ChatGPT and Claude the library they’re missing: a biopharma knowledge base, already matched and checked, with a source on every value. On their own, they’re strong analysts who rebuild each landscape from the open web, can’t reach sell-side research or China’s registries, and get some of it wrong. Connect Sleuth, and Claude, ChatGPT, or Copilot work from the same knowledge base. See how Sleuth compares with ChatGPT and Claude.

Can Sleuth replace Evaluate, Cortellis, Citeline, or GlobalData?

Yes, for most biopharma strategy work. Every plan includes the same kinds of records, connected in Sleuth’s knowledge base: programs by target, modality, and phase, with catalysts and sales forecasts; trials from registries worldwide; and deals with upfronts, milestones, and royalties where they’re disclosed. Sleuth adds sell-side research and China coverage, and browsing is free and never uses credits. Then Sleuth does the narrowing down you’d otherwise do in Excel. Compare Sleuth with your database.

Where does Sleuth’s data come from?

Sleuth’s data comes from the organizations that publish it: trial registries, regulators, patents, journals, companies, news, and sell-side research from 35+ providers, including China’s sources in Chinese. Sleuth checks every record and keeps it current. Every source is listed on the Data page.

How accurate is Sleuth?

Every value in a Sleuth dataset links to its source and has a confidence score, based on how good its best source is, whether independent sources agree, and, where it matters, how recent it is. When Sleuth can’t find a source for a value, it marks it unknown instead of filling it in, so you can see what to trust and what to check. See how Sleuth scores every value.

Can we use Sleuth with our own documents and data?

Yes. Sleuth works with your own documents on any plan: upload your files, and Sleuth reads them alongside everything else, or start a project from your own spreadsheet. On Enterprise, Sleuth also connects to Drive, SharePoint, Box, or your data warehouse and matches your internal program names to the same records. Talk to us about connecting your systems.

What does it cost to start?

Starting Sleuth costs nothing: the free trial gives you 14 days of everything in Starter, with 2,500 credits for analysis and no card. After that, plans start at $249 a month, and browsing the knowledge base never uses credits. See every plan on the Pricing page.

Run your first analysis on your own program

Set up in Claude, ChatGPT, or Copilot